Middle East Conflict Impacts Australia and New Zealand Businesses 
GameStop Eyes eBay Acquisition as Stock Prices Surge After Hours 
Hugo Boss Beats Q1 Profit Expectations Despite Market Headwinds 
Berkshire Hathaway Q1 Earnings Jump 18% as Greg Abel Signals Disciplined Growth Strategy 
NAB First-Half Earnings Miss Forecasts Amid Rising Global Risks 
Standard Chartered Q1 Profit Hits Record on Wealth and Investment Banking Growth 
Apple Explores Intel and Samsung Partnerships to Diversify Chip Supply Chain 
Amazon Stock Dips Despite Record Earnings as AI Infrastructure Spending Surges 
Palantir Reports Record Growth, Raises 2026 Revenue Outlook Above Expectations 
Supreme Court Asked to Reinstate Mail-Order Access to Abortion Pill Mifepristone 
Meta Raises 2026 Capex Outlook Amid AI Spending Surge, Shares Drop After Earnings 
Pinterest Stock Surges After Strong Q1 2026 Earnings Beat Expectations 
Samsung Appoints New TV Business Head Amid Rising Competition from Chinese Rivals 
Anthropic Secures $1.5B AI Venture Backed by Wall Street Giants, Shaking Software Sector 
GameStop Proposes $56 Billion eBay Acquisition in Bold Strategic Move 
Spirit Airlines Shuts Down Flights, Issues Refunds After Financial Collapse 
Volvo Car Sales Drop 10% in Early 2026 Despite Growth in Electric Vehicles 
Heidelberg, Germany, May 3, 2018 - Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, announced today that Dr. Adi Hoess, CEO, will present at Deutsche Bank's 43rd Annual Health Care Conference on Tuesday, May 8, 2018 at 10:40 am ET.
A live webcast of the conference presentation can be accessed through the "Events" section on the "Investors & Media" page of the Affimed website at www.affimed.com/events.php. A replay of the presentation will be available from Affimed's website for 30 days following the conference.
About Affimed N.V.
Affimed (Nasdaq: AFMD) engineers targeted immunotherapies, seeking to cure patients by harnessing the power of innate and adaptive immunity (NK and T cells). We are developing single and combination therapies to treat cancers and other life-threatening diseases. For more information, please visit www.affimed.com.
Contact:
Anca Alexandru, Head of Communications, EU IR
Phone: +49 6221 64793341
E-Mail: [email protected], I[email protected]
